



## News Release

Contact: Derma Sciences Inc  
Edward J. Quilty  
Chairman and CEO  
[equilty@dermasciences.com](mailto:equilty@dermasciences.com)  
(609) 514-4744

Allen & Caron Inc  
Rudy Barrio (US Investors)  
[r.barrio@allencaron.com](mailto:r.barrio@allencaron.com)

Brian Kennedy (media)  
[brian@allencaron.com](mailto:brian@allencaron.com)  
(212) 691-8087

### **Derma Sciences Announces Several Clinical Presentations on MEDIHONEY™ Wound & Burn Dressings at Upcoming APWCA Conference**

*Evidence Base for MEDIHONEY™ Dressings Growing*

**PRINCETON, NJ – (February 20, 2008)** . . . Derma Sciences, Inc. (OTCBB: DSCI), a provider of advanced wound care products, announced today that four abstracts detailing the clinical usage of its newly released MEDIHONEY™ Wound & Burn Dressings with Active *Leptospermum* Honey were accepted for presentation at the upcoming annual American Professional Wound Care Association conference, held this year between March 6 – 9 in Fort Worth, Texas. Additionally, the company has announced that the use of MEDIHONEY™ Dressings is a topic on the general session agenda for the conference.

About the product's recognition at the upcoming conference, CEO Edward Quilty said, "The fact that so many abstracts were developed and accepted at a national conference after only four months on the market speaks volumes to the effectiveness of the MEDIHONEY™ dressings. Based on the response and clinical evidence generated while on the market in Europe over the past two years, we had a good sense of what would happen upon our launch in the US and Canada. It is exciting to see the product meeting our very high expectations, and to know that we are contributing to the well-being of many patients who would otherwise have very few options."

The abstracts include the following:

"Chronic Lower Extremity Ulceration – Use of a *Leptospermum* Impregnated Alginate to Accelerate Wound Closure", Dr. Matt Regulski, DPM, Toms River Foot and Ankle Surgical Associates, New Jersey.

"Clinical Application of Absorbent Calcium Alginate Dressing Pads, Containing Manuka (*Leptospermum*) Honey, in Infected Lower Extremity Venous Ulcers", Dr. Paul Kesselman, DPM, Brooklyn, NY

"Favorable Treatment Outcomes of Chronic Leg Ulcers with the Use of a New *Leptospermum* Honey Alginate Dressing", Dr. Paul A. Ligouri, MD and Kim L. Peters, RN, CWS, Whittier Rehabilitation Hospital, Haverhill, MA.

"Utilizing *Leptospermum* Honey Alginate in Treatment of Recalcitrant Lower Extremity Ulcers", Dr. Steven J. Kavros, DPM, Mayo Clinic, Rochester, MN.

In addition to these presentations, the first topic on the conference's general session agenda following the keynote address will be "MEDIHONEY™: An Update on the Newly Approved Natural Approach to Chronic Wounds", to be presented by Dr. Robert Frykberg, DPM, FAPWCA, MPH, Chief of Podiatry, Carl T. Hayden VA Medical Center in Phoenix, AZ. In this session Dr. Frykberg will be providing an update on his continuing case series related to the treatment of recalcitrant diabetic foot ulcers with MEDIHONEY™ dressings, first presented at the Clinical Symposium on Advances in Skin and Wound Care last October.

MEDIHONEY is the first FDA-cleared honey-based dressing for use on chronic wounds and burns, and is the only FDA-cleared honey-based product currently commercialized. Its key ingredient, Active *Leptospermum* Honey, has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large scale randomized controlled studies on leg ulcers. After four months on the market, the company has made the decision to expand its sales force to meet the high demand for this unique wound care device.

MORE-MORE-MORE

## Derma Sciences Announces Several Clinical Presentations on MEDIHONEY™ Wound & Burn Dressings at Upcoming APWCA Conference

Page 2-2-2

### **About Derma Sciences**

Derma Sciences is a manufacturer and marketer of advanced wound-care products, with operations based in the US and Canada, and sales worldwide. The company recently launched its MEDIHONEY™ Wound & Burn dressings with Active *Leptospermum* Honey. The Company has also obtained FDA clearance to market and sell its MOBILITY-1™ boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at [www.dermasciences.com](http://www.dermasciences.com).

### **About the APWCA**

The American Professional Wound Care Association (APWCA) is a hybrid non-profit organization whose membership incorporates the various medical specialties involved in providing all aspects of wound care. Its seminars bring these fields together and facilitate an integrated, multi-disciplinary approach. The mission of the Association is to help decrease the rate of complications from all wounds, including acute, chronic, post surgical, post radiation, reconstructive and other problematic wounds. The organization's stated goal is to accelerate wound healing and preserve and/or enhance the quality of life for these patients. For more information about the APWCA, visit its home page at [www.apwca.org](http://www.apwca.org).

### **Forward-looking Statements**

*Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.*

# # #